Terms: = Thyroid cancer AND TSHR, hTSHR-I, 7253, ENSG00000165409, MGC75129, LGR3 AND Prognosis
24 results:
1. thyroid dysfunction caused by exposure to environmental endocrine disruptors and the underlying mechanism: A review.
He J; Xu J; Zheng M; Pan K; Yang L; Ma L; Wang C; Yu J
Chem Biol Interact; 2024 Mar; 391():110909. PubMed ID: 38340975
[TBL] [Abstract] [Full Text] [Related]
2. Somatostatin Receptor Type 2 and thyroid-Stimulating Hormone Receptor Expression in Oncocytic thyroid Neoplasms: Implications for prognosis and Treatment.
Gillis A; Zheng-Pywell R; McLeod C; Wang D; Ness JM; Guenter R; Whitt J; Prolla TA; Chen H; Gonzalez ML; Rose B; Lloyd RV; Jaskula-Sztul R; Lin D
Mod Pathol; 2023 Dec; 36(12):100332. PubMed ID: 37716507
[TBL] [Abstract] [Full Text] [Related]
3. Whole-genome Sequencing of Follicular thyroid Carcinomas Reveal Recurrent Mutations in MicroRNA Processing Subunit DGCR8.
Paulsson JO; Rafati N; DiLorenzo S; Chen Y; Haglund F; Zedenius J; Juhlin CC
J Clin Endocrinol Metab; 2021 Oct; 106(11):3265-3282. PubMed ID: 34171097
[TBL] [Abstract] [Full Text] [Related]
4. Mutation profiles of follicular thyroid tumors by targeted sequencing.
Duan H; Liu X; Ren X; Zhang H; Wu H; Liang Z
Diagn Pathol; 2019 May; 14(1):39. PubMed ID: 31077238
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive Genetic Analysis of Follicular thyroid Carcinoma Predicts prognosis Independent of Histology.
Nicolson NG; Murtha TD; Dong W; Paulsson JO; Choi J; Barbieri AL; Brown TC; Kunstman JW; Larsson C; Prasad ML; Korah R; Lifton RP; Juhlin CC; Carling T
J Clin Endocrinol Metab; 2018 Jul; 103(7):2640-2650. PubMed ID: 29726952
[TBL] [Abstract] [Full Text] [Related]
6. Identification of Functional thyroid Stimulating Hormone Receptor and
Shih YL; Huang YH; Lin KH; Chu YD; Yeh CT
Anticancer Res; 2018 May; 38(5):2793-2802. PubMed ID: 29715101
[TBL] [Abstract] [Full Text] [Related]
7. thyroid-stimulating hormone receptor affects metastasis and prognosis in papillary thyroid carcinoma.
Liu TR; Su X; Qiu WS; Chen WC; Men QQ; Zou L; Li ZQ; Fu XY; Yang AK
Eur Rev Med Pharmacol Sci; 2016 Sep; 20(17):3582-91. PubMed ID: 27649658
[TBL] [Abstract] [Full Text] [Related]
8. Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.
Jung SH; Kim MS; Jung CK; Park HC; Kim SY; Liu J; Bae JS; Lee SH; Kim TM; Lee SH; Chung YJ
Oncotarget; 2016 Oct; 7(43):69638-69648. PubMed ID: 27626165
[TBL] [Abstract] [Full Text] [Related]
9. Interaction of Age at Diagnosis with Transcriptional Profiling in Papillary thyroid cancer.
Hsu YC; Liu CL; Yang PS; Tsai CH; Lee JJ; Cheng SP
World J Surg; 2016 Dec; 40(12):2922-2929. PubMed ID: 27384173
[TBL] [Abstract] [Full Text] [Related]
10. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract] [Full Text] [Related]
11. Mutations of tshr and TP53 Genes in an Aggressive Clear Cell Follicular Carcinoma of the thyroid.
Tong GX; Mody K; Wang Z; Hamele-Bena D; Nikiforova MN; Nikiforov YE
Endocr Pathol; 2015 Dec; 26(4):315-9. PubMed ID: 26260781
[TBL] [Abstract] [Full Text] [Related]
12. (99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer.
Galli F; Manni I; Piaggio G; Balogh L; Weintraub BD; Szkudlinski MW; Fremont V; Dierckx RA; Signore A
Thyroid; 2014 Aug; 24(8):1297-308. PubMed ID: 24801227
[TBL] [Abstract] [Full Text] [Related]
13. In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma.
Dong JJ; Zhou Y; Liu YT; Zhang ZW; Zhou XJ; Wang HJ; Liao L
Mol Cell Endocrinol; 2013 May; 370(1-2):113-8. PubMed ID: 23462194
[TBL] [Abstract] [Full Text] [Related]
14. CD133-expressing thyroid cancer cells are undifferentiated, radioresistant and survive radioiodide therapy.
Ke CC; Liu RS; Yang AH; Liu CS; Chi CW; Tseng LM; Tsai YF; Ho JH; Lee CH; Lee OK
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):61-71. PubMed ID: 23081821
[TBL] [Abstract] [Full Text] [Related]
15. Dedifferentiation of differentiated thyroid carcinoma cell line FTC-133 is enhanced by 131I pretreatment.
Feng F; Wang H; Fu H; Wu S; Ye Z; Chen S; Li J
Nucl Med Biol; 2011 Oct; 38(7):1053-8. PubMed ID: 21982575
[TBL] [Abstract] [Full Text] [Related]
16. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.
Oler G; Cerutti JM
Cancer; 2009 Mar; 115(5):972-80. PubMed ID: 19152441
[TBL] [Abstract] [Full Text] [Related]
17. Methylation status of genes in papillary thyroid carcinoma.
Smith JA; Fan CY; Zou C; Bodenner D; Kokoska MS
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1006-11. PubMed ID: 17938324
[TBL] [Abstract] [Full Text] [Related]
18. [Cellular tumor markers in thyroid cancer].
Kopczyńska E; Kwapisz J; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2007 Apr; 22(130):295-9. PubMed ID: 17684930
[TBL] [Abstract] [Full Text] [Related]
19. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
[TBL] [Abstract] [Full Text] [Related]
20. [thyroid carcinomas of the follicular epithelium: tumor markers and oncogenes].
Alvarez-Núñez F; Mora J; Matías-Guiu X;
Med Clin (Barc); 2003 Sep; 121(7):264-9. PubMed ID: 12975039
[TBL] [Abstract] [Full Text] [Related]
[Next]
